946420-68-4

Basic information

• Product Name: N-[(1S,2R)-2-azido-1-benzyl-3-fluoropropyl]-2-[(isopropylsulfonyl)(methyl)amino]-6-(methyl{[(1S,2S)-2-methylcyclopropyl]methyl}amino)isonicotinamide
• Synonyms: N-[(1S,2R)-2-azido-1-benzyl-3-fluoropropyl]-2-[(isopropylsulfonyl)(methyl)amino]-6-(methyl{[(1S,2S)-2-methylcyclopropyl]methyl}amino)isonicotinamide
• CAS NO: 946420-68-4
• Molecular Weight: 545.681
• Mol File: 946420-68-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-[(1S,2R)-2-azido-1-benzyl-3-fluoropropyl]-2-[(isopropylsulfonyl)(methyl)amino]-6-(methyl{[(1S,2S)-2-methylcyclopropyl]methyl}amino)isonicotinamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(1S,2R)-2-azido-1-benzyl-3-fluoropropyl]-2-[(isopropylsulfonyl)(methyl)amino]-6-(methyl{[(1S,2S)-2-methylcyclopropyl]methyl}amino)isonicotinamide(946420-68-4)
• EPA Substance Registry System: N-[(1S,2R)-2-azido-1-benzyl-3-fluoropropyl]-2-[(isopropylsulfonyl)(methyl)amino]-6-(methyl{[(1S,2S)-2-methylcyclopropyl]methyl}amino)isonicotinamide(946420-68-4)

Safety Data

• Hazardous Substances Data: 946420-68-4(Hazardous Substances Data)

Upstream product

• 935470-40-9 2-[(isopropylsulfonyl)(methyl)amino]-6-(methyl{[(1S,2S)-2-methylcyclopropyl]methyl}amino)isonicotinic acid 
• 935470-47-6 N-benzyl[(1S,2S)-2-methylcyclopropyl]methanamine 
• 935470-34-1 methyl 2-chloro-6-[(isopropylsulfonyl)(methyl)amino]isonicotinate 
• 935470-36-3 2-chloro-6-[(isopropylsulfonyl)(methyl)amino]isonicotinic acid 
• 98760-08-8 (1-oxiranyl-2-phenylethyl)carbamic acid tert-butyl ester 
• 42521-09-5 methyl 2,6-dichloroisonicotinate 
• 946420-64-0 tert-butyl [(1S,2R)-2-azido-1-benzyl-3-fluoropropyl]carbamate 
• 946420-63-9 tert-butyl [(1S,2S)-1-benzyl-3-fluoro-2-hydroxypropyl]carbamate 

Relevant articles and documents

Discovery of isonicotinamide derived β-secretase inhibitors: In vivo reduction of β-amyloid

β-Secretase inhibition offers an exciting opportunity for therapeutic intervention in the progression of Alzheimer's disease. A series of isonicotinamides derived from traditional aspartyl protease transition state isostere inhibitors has been optimized to yield low nanomolar inhibitors with sufficient penetration across the blood-brain barrier to demonstrate β-amyloid lowering in a murine model.